Hawkinsinuria
Hawkinsinuria | |
Hawkinsin | |
OMIM | 276710 140350 |
DiseasesDB | 29836 |
MeSH | D020176 |
WikiDoc Resources for Hawkinsinuria |
Articles |
---|
Most recent articles on Hawkinsinuria Most cited articles on Hawkinsinuria |
Media |
Powerpoint slides on Hawkinsinuria |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Hawkinsinuria at Clinical Trials.gov Trial results on Hawkinsinuria Clinical Trials on Hawkinsinuria at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Hawkinsinuria NICE Guidance on Hawkinsinuria
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Hawkinsinuria Discussion groups on Hawkinsinuria Patient Handouts on Hawkinsinuria Directions to Hospitals Treating Hawkinsinuria Risk calculators and risk factors for Hawkinsinuria
|
Healthcare Provider Resources |
Causes & Risk Factors for Hawkinsinuria |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Hawkinsinuria, also called 4-Alpha-hydroxyphenylpyruvate hydroxylase deficiency, is an autosomal dominant metabolic disorder affecting the metabolism of the sulfur amino acid hawkinsin.[1]
It is characterized by transient metabolic acidosis and tyrosinemia.
See also
References
- ↑ Tomoeda K, Awata H, Matsuura T, Matsuda I, Ploechl E, Milovac T, Boneh A, Scott CR, Danks DM, Endo F (2000). "Mutations in the 4-hydroxyphenylpyruvic acid dioxygenase gene are responsible for tyrosinemia type III and hawkinsinuria". Mol Genet Metab. 71 (3): 506–510. doi:10.1006/mgme.2000.3085. PMID 11073718.